DSpace About DSpace Software 日本語
 

GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2020年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/3825

Title: Ring box protein-1 is associated with a poor prognosis and tumor progression in esophageal cancer.
Other Titles: Ring box protein-1 は食道癌の予後不良因子であり、腫瘍の進行と関連している
Authors: Kunishige, Tomohiro
Migita, Kazuhiro
Matsumoto, Sohei
Wakatsuki, Kohei
Nakade, Hiroshi
Miyao, Shintaro
Kuniyasu, Hiroki
Sho, Masayuki
Keywords: ring box protein-1
prognostic factor
proliferation
chemotherapy
esophageal cancer
Issue Date: Sep-2020
Publisher: Spandidos Publications
Citation: Oncology letters Vol.20 No.3 p.2919-2927 (2020 Sep)
Abstract: Ring box protein-1 (RBX1) is an essential component of the S-phase kinase-associated protein, Cullin and F-box containing ubiquitin ligases. Overexpression of RBX1 has been reported in several cancer types; however, little is known regarding the prognostic value and role of RBX1 in esophageal cancer. The present study examined 120 patients with esophageal cancer (EC) who underwent curative esophagectomy and 61 patients with EC who underwent neoadjuvant combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (5-FU; DCF) using immunohistochemistry. All specimens were classified into two groups according to the percentage of RBX1-positive tumor cells. In addition, the impact of RBX1 expression on cancer cell proliferation was analyzed in vitro using a small interfering RNA silencing technique. RBX1 expression levels showed significant differences according to tumor size (P<0.001), tumor depth (P=0.002), lymph node metastasis (P=0.004), pathological stage (P=0.001), lymphatic invasion (P=0.001) and venous invasion (P=0.001). The overall survival (OS) rate in the RBX1 high expression group was significantly lower compared with that in the low group (P=0.004). Multivariate analysis demonstrated that RBX1 status was an independent prognostic factor. RBX1 gene silencing inhibited the proliferation of human EC cells and enhanced the antitumor effect of 5-FU. Among patients who underwent neoadjuvant DCF therapy, the RBX1 high expression group had a significantly lower OS rate compared with that of the RBX1-low group (P<0.001). In conclusion, RBX1 has notable prognostic value, and RBX1 may serve an important function in the tumor progression of EC.
Description: 博士(医学)・乙第1480号・令和2年12月24日
Copyright: © Kunishigeet al. This is an open access article distributed under theterms of CreativeCommons Attribution License(https://creativecommons.org/licenses/by-nc-nd/4.0/).
URI: http://hdl.handle.net/10564/3825
ISSN: 17921074
Academic Degrees and number: 24601B1480
Degree-granting date: 2020-12-24
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2020年度

Files in This Item:

File Description SizeFormat
01乙1480本文の要旨.pdf乙1480本文の要旨1.55 MBAdobe PDFView/Open
02乙1480審査要旨.pdf乙1480審査要旨83.08 kBAdobe PDFView/Open
03乙1480本文.pdf乙1480本文664.56 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback